EG
CAPR icon

Ellerson Group’s Capricor Therapeutics CAPR Stock Holding History

Ellerson Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,890
Closed -$240K – 65
2026
Q1 		$240K Sell
7,890
-1,800
-19% -$48K 0.16% 50
2025
Q4 		$280K Sell
9,690
-7,410
-43% -$96.8K 0.19% 44
2025
Q3 		$123K Hold
17,100
– – 0.08% 59
2025
Q2 		$170K Buy
+17,100
New +$181K 0.12% 53

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ellerson Group's CAPR Position: Q2 2026 in Review

Ellerson Group sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 7,890 shares — an estimated $240K sold.

Ellerson Group first reported a position in CAPR in Q2 2025 and held it in 4 quarters. The position peaked at $280K in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Ellerson Group reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ellerson Group sold 7,890 Capricor Therapeutics shares in Q2 2026, an estimated $240K.
  • Ellerson Group first reported a position in Capricor Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ellerson Group's Capricor Therapeutics position peaked at $280K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Ellerson Group's 13F filing for Q2 2026, filed 31 Jul 2026.